Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.

Lisa Aniek de JongJudith J Gout-ZwartMarina van den BoschMike KoopsMaarten Jacobus Postma

Published in: Journal of medical economics (2019)

In patients with NVAF or VTE, rivaroxaban treatment is likely to be cost-effective and a potentially cost-saving alternative to VKA in the Netherlands.

Keyphrases

venous thromboembolism
atrial fibrillation
direct oral anticoagulants
oral anticoagulants
left atrial
catheter ablation
heart failure
left atrial appendage
electronic health record
big data
percutaneous coronary intervention
aortic valve
data analysis
mitral valve